• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

SpectraCure

0.05 SEK

-56.23 %

Less than 1K followers

SPEC

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-56.23 %
-15.72 %
-44.15 %
-66.62 %
-68.52 %
-86.51 %
-98.09 %
-98.69 %
-91.67 %

SpectraCure operates in the medical technology sector. The company specializes in research and development of medical technology systems used for the treatment of prostate cancer. The cancer treatments are based on proprietary systems that emit laser light sources and photoreactive drugs, a treatment methodology used for internal solid tumors of various types. The largest operations are found in the Nordic market. The company has its headquarters in Lund.

Read more
Market cap
29.67M SEK
Turnover
1.28M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
15/7
2026

Extraordinary general meeting '26

21/8
2026

Interim report Q2'26

13/11
2026

Interim report Q3'26

Regulatory press release5 hours ago

KALLELSE TILL EXTRA BOLAGSSTÄMMA I SPECTRACURE AB (PUBL)

SpectraCure
Regulatory press release5 hours ago

Styrelsen i SpectraCure har beslutat om en företrädesemission om cirka 34,2 MSEK

SpectraCure
Regulatory press release6/1/2026, 11:25 AM

SpectraCure tillsätter ny CFO

SpectraCure

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/27/2026, 1:00 PM

Årsstämma i SpectraCure AB (publ) den 27 maj 2026

SpectraCure
Regulatory press release5/27/2026, 9:00 AM

SpectraCure AB (publ): Kvartalsrapport för januari – mars 2026

SpectraCure
Press release5/13/2026, 6:40 AM

Uppdatering om SpectraCures kliniska studier inom prostatacancer

SpectraCure
Regulatory press release5/5/2026, 4:40 PM

SpectraCure publicerar årsredovisning för 2025

SpectraCure
Press release5/5/2026, 10:00 AM

SpectraCure ökar sitt ägande i Deep Light Vision genom kvittningsemission

SpectraCure
Regulatory press release4/22/2026, 1:35 PM

KALLELSE TILL ÅRSSTÄMMA I SPECTRACURE AB (PUBL)

SpectraCure
Regulatory press release2/27/2026, 10:00 AM

SpectraCure AB (publ): Bokslutskommuniké för januari - december 2025

SpectraCure
Regulatory press release2/5/2026, 9:15 AM

SpectraCure AB beslutar om ersättningsemission till garanter i samband med att nyttjandeperioden för teckningsoptioner av serie TO5 löpt ut

SpectraCure
Regulatory press release1/29/2026, 4:15 PM

SpectraCure AB genomför riktad nyemission till garanter i samband med avslutad nyttjandeperiod av teckningsoptioner av serie TO5

SpectraCure
Regulatory press release1/29/2026, 4:10 PM

SpectraCure AB tillförs cirka 15,6 MSEK genom teckningsoptioner av serie TO5

SpectraCure
Regulatory press release1/26/2026, 12:40 PM

SpectraCure tecknar avtal med ytterligare sjukhus i Tyskland för klinisk studie av primär lokaliserad prostatacancer

SpectraCure
Press release1/23/2026, 8:00 AM

SpectraCures VD Johannes Swartling intervjuas om bolagets verksamhet och strategi

SpectraCure
Press release1/23/2026, 7:00 AM

Sista dag för handel med teckningsoptionerna av serie TO5 i SpectraCure är idag den 23 januari 2026

SpectraCure
Regulatory press release1/21/2026, 7:15 AM

SpectraCure har säkerställt 50 procent av teckningsoptionerna av serie TO5 om cirka 15,6 MSEK

SpectraCure
Press release1/20/2026, 11:35 AM

Rapporterade resultat i SpectraCures kliniska studier

SpectraCure
Regulatory press release1/15/2026, 8:20 AM

Medlemmar ur styrelsen har åtagit sig att nyttja samtliga innehavda teckningsoptioner om cirka 1,3 MSEK, motsvarande 4,1 procent av utestående teckningsoptioner av serie TO5

SpectraCure
Regulatory press release1/14/2026, 8:22 AM

Nyttjandeperioden för teckningsoptioner av serie TO5 i SpectraCure inleds idag

SpectraCure